Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164722 · ClinicalTrials.gov registry record · Phase 3
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Phase 3 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT01164722 is a Phase 3 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 120 participants.
The verdict
NCT01164722, a Phase 3 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: Infrared coagulator ablation may be effective in preventing the development of anal cancer in patients with anal neoplasia PURPOSE: This randomized phase III trial is studying infrared coagulator ablation to see how well it works compared to observation in preventing anal cancer in HIV-positive patients with anal neoplasia.
Interventions
- DEVICE infrared photocoagulation therapy
- OTHER clinical observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164722
The ClinicalTrials.gov registry entry for NCT01164722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which infrared photocoagulation therapy is the first listed.
NCT01164722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01164722 about?
NCT01164722 is a clinical study titled "Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia". RATIONALE: Infrared coagulator ablation may be effective in preventing the development of anal cancer in patients with anal neoplasia PURPOSE: This randomized phase III trial is studying infrared coagulator ablation to see how well it works compared to observation in preventing anal cancer in HIV-p...
What is the current status of trial NCT01164722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2011-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01164722?
The interventions under investigation include: infrared photocoagulation therapy (DEVICE), clinical observation (OTHER).
Who is sponsoring clinical trial NCT01164722?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.